medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2018, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2018; 34 (3)

Hemovigilance of side effects related to blood donation

Silva BHM, Bencomo HA, Díaz AB, Zangroniz CD

Language: Spanish
References: 19
Page: 1-18
PDF size: 376.61 Kb.


ABSTRACT

Blood donation is the livelihood of all blood programs to provide safe blood transfusion for therapeutic use whit the aim to preserve health and human life. It is necessary to pay attention to the safety and quality of this activity, because is an ethical principle to take care of the health of those who, in an altruist manner, give part of themselves in order to benefit others. Although the donation is a safe procedure, occasionally some side effects in donors may occur, many of them can be avoided, and that could have an echo on the donors' health on effect their return to this activity. At the beginning of the 90 ths, decade started the Hemovigilance programs in charge of the vigilance, notification and prevention of transfusion and donation side effects, whit the purpose of preventing its recurrence and increase the safety and quality of both procedures. This work carries out and update revision about of donor's reactions in the Hemovigilance.


REFERENCES

  1. Organización Panamericana de la Salud. Plan de acción para el acceso universal a sangre segura [Internet]. 53.º Consejo Directivo de la OPS, 66.a sesión del Comité Regional de la OMS para las Américas; del 29 de septiembre al 3 de octubre del 2014; Washington, DC. Washington, DC: OPS; (documento CD53/6) [consultado el 25 de enero del 2017]. Disponible en: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=26748&Ite mid=270&lang=es

  2. Benjamin RJ. Donor hemovigilance safety as the first priority of the blood donor management. ISBT Sci Ser; 2010 Jul;5(1):206-11.

  3. Newman BH. Donor reactions and injuries from whole blood donation. Transfus Med Rev. 1997;11(1):64-75.

  4. Eder A, Goldman M, Rossmann S, Waxman D, Bianco C. Selection criteria to protect the blood donor in North America and Europe: past(dogma), present (evidence), and future (haemovigilance).Transfus Med Rev. 2009;23(3):205-20.

  5. Wiersum-Osselton JC, Marijt van der Kreek T, de Kort WL. Donor vigilance: What are we doing about ?. Biologicals. 2012 May;40(3):176-9. doi: 10.1016/j.biologicals.2011.12.003.

  6. Nakajima K. Donor complications and donor care. ISBT Sci Ser. 2009;4(2):411-7.

  7. Silva Ballester HM, Bencomo Hernández A, Benet Rodriguez CM, López Fernández R, Valls W, Ballester Santovenia JM. La Hemovigilancia de las reacciones adversas de la donación. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2013 Jun [citado 2016 Ago 20] ;29(2):154-162. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892013000200006&lng=es

  8. Amorin LA, Faría NA, Andrade RA, López ME. Haemovigilance focused on blood donors reactions:a new tool for improving donor care. Abstract of the XVIIth Regional Congress of the ISBT, Madrid.Spain. Vox Sang [serie en Internet]. 2007 Jul [citado 12 Dic 2009];93(Suppl 1):237-8.

  9. European Heart Network. Working Group on Complications Related to Blood Donation. Standard for Surveillance of complications Related to Blood Donation [monografía en Internet]. 2008 [citado 10 Dic 2012];1-11. Disponible en: http://www.isbtweb.org/members_only/files/society/DOCO%20Standard%202007%20Form%20 %20Final.pdf

  10. Working Group ISBT/IHN. Standard for surveillance of complications related to blood donation. 2014 (Accedido: octubre 18, 2016). Disponible en: http://www.aabb.org/research/hemovigilance/Documents/Standard-for-Surveillance-of- Complications-Related-to-Blood-Donation.pdf

  11. Goldman M, Land K, Robillard P, Wiersum-Osselton J. Development of standard definitions for surveillance of complications related to blood donation. Vox Sang. 2016 Feb;110(2):185-8. doi: 10.1111/vox.12323.

  12. Muñiz-Díaz E, León G, Torres O. Manual iberoamericano de hemovigilancia. Barcelona: Texto y Color 65;2015. [citado 10 Dic 2016] Disponible en: https://www.dropbox.com/s/94ag1v1egmew8pf/Manual%20Iberoamericano%20de%20Hemovigi lancia.pdf?dl=0

  13. Mörtzell Henriksson M, Newman E, Witt V, Derfler K, Leitner G, Eloot S, et al. Adverse events in Apheresis: An update of the WAA registry data.Tranfus Apher Sci. 2016 Feb;54(1):2- 15. doi: 10.1016/j.transci.2016.01.003.

  14. Boot CL, Luken JS, van den Burg PJ, de Kort WL, Koopman MM, Vrielink H, et al . Bone density in apheresis donors and whole blood donors. Vox Sang. 2015 Nov;109(4):410-3. doi: 10.1111/vox.12299.

  15. Lieshout-Krikke RW, Zaaijer HL, van de Laar TJ. Predonation screening of candidate donors and prevention of window period donations. Transfusion. 2015 Feb;55(2):373-8. doi: 10.1111/trf.12809.

  16. Kiss JE. Oral iron supplementation after blood donation a randomized clinical trials. JAMA. 2015.313:575-83.

  17. Wiersum-Osselton JC, Marijt van der Kreek T, Bokhorst AG, de Kort WLAM. Donor vigilance: a global update. ISBT Sci Ser. 2014;9:228-33.

  18. Silva Ballester HM, Bencomo Hernández A, Benet Rodriguez CM, López Fernández R, Valls W, Ballester Santovenia JM. Una experiencia pionera en la Hemovigilancia. Boletín de la a Sociedad Española de Medicina Transfusional y Terapia celular (No. 90) SETS. 2014;26(3):21-5.

  19. Ounnoughene N, Sandid I, Carlier M, Joussemet M, Ferry N. The blood donors' haemovigilance in France. Transfus Clin Biol. 2013 May;20(2):182-92.




2020     |     www.medigraphic.com